These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9815565)

  • 1. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
    Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
    Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
    Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Jeglum KA; Santoli D
    Clin Cancer Res; 1999 Jul; 5(7):1868-75. PubMed ID: 10430094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
    Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
    Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
    Cesano A; Visonneau S; Santoli D
    Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
    Visonneau S; Cesano A; Torosian MH; Santoli D
    Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
    Cesano A; Visonneau S; Santoli D
    Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary malignant histiocytosis of the brain in a dog.
    Chandra AM; Ginn PE
    J Comp Pathol; 1999 Jul; 121(1):77-82. PubMed ID: 10373296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
    Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
    Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
    Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
    Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
    Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma.
    Jeglum KA; Young KM; Barnsley K; Whereat A; McGrath D; Hutson C
    J Biol Response Mod; 1986 Apr; 5(2):168-75. PubMed ID: 3734843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
    Cesano A; Visonneau S; Rovera G; Santoli D
    Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
    Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
    Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
    Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
    Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma.
    Lupu M; Sullivan EW; Westfall TE; Little MT; Weigler BJ; Moore PF; Stroup PA; Zellmer E; Kuhr C; Storb R
    J Am Vet Med Assoc; 2006 Mar; 228(5):728-32. PubMed ID: 16506937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.